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ABSTRACT
Imatinib is the first molecularly targeted compound for chronic myeloid leukemia (CML) capable to
inhibit BCR-ABL kinase activity. However, recent clinical evidence indicates that a substantial proportion
of CML patients exhibit BCR-ABL-dependent or independent resistance to imatinib. Despite the impor-
tance of imatinib resistance in CML, the underlying molecular mechanisms of this resistance are largely
unknown. Here, we identified GCA (grancalcin) as a critical regulator of imatinib resistance in chronic
phase CML via activation of autophagy. Mechanistically, we demonstrated that GCA activates TRAF6
ubiquitin ligase activity to induce Lys63 ubiquitination of ULK1, a crucial regulator of autophagy,
resulting in its stabilization and activation. We also highlighted the role of GCA-TRAF6-ULK1 autophagy
regulatory axis in imatinib resistance. Our findings represent the basis for novel therapeutic strategies
against CML.
Abbreviation: ACTB/β-actin: actin beta; ADM: adrenomedullin; AMBRA1: autophagy and beclin 1
regulator 1; AMPK: AMP-activated protein kinase; ANXA5: annexin A5; CP: cytogenetic response; CML:
chronic myeloid leukemia; CUL3: cullin 3; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GCA:
grancalcin; Dx: at diagnosis; E-64-d: (2S,3S)-trans-Epoxysuccinyl-L-leucylamido-3-methylbutane ethyl
ester; IMres: Imatinib resistance; KLHL20: Kelch-like protein 20; LRMP: lymphoid-restricted membrane
protein; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MMR: major molecular response;
NH4Cl: ammonium chloride; PBMCs: peripheral blood mononuclear cells; PTPRC: protein tyrosine phos-
phatase, receptor type, C; SQSTM1/p62: sequestosome 1; SYK: spleen associated tyrosine kinase; TAP1:
transporter 1, ATP binding cassette subfamily B member; TKIs: ABL-specific tyrosine kinase inhibitors;
TLR9: toll- like receptor 9; TRAF6: TNF receptor associated factor 6; ULK1: unc-51 like autophagy
activating kinase 1
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Chronic myeloid leukemia (CML) is a malignant myeloproli-
ferative disorder resulting from the clonal expansion of
a transformed multipotent hematopoietic stem cell [1]. CML
is characterized by the formation of BCR-ABL chimeric onco-
protein with constitutive ABL tyrosine kinase activity [2,3].
The deregulated ABL tyrosine kinase activity promotes cell
survival and proliferation while inhibiting apoptosis [4]. ABL-
specific tyrosine kinase inhibitors (TKIs) that selectively inhi-
bit the growth of BCR-ABL–positive CML cells in vitro [5]
and in vivo [6] are widely used to treat CML [7]. Imatinib, the
first designed TKI, represents effective therapy for CML [8].
Despite these impressive results, a few patients are resistant to
imatinib. Approximately 10% of CML patients show primary
imatinib resistance within 3 months of imatinib treatment
[9,10]. Furthermore, nearly 20% of CML patients in chronic
phase (CML-CP), who were previously sensitive to imatinib,
develop resistance [11,12].
The most frequently identified mechanism of acquired
secondary imatinib resistance involves point mutations
associated with BCR-ABL kinase domain that inhibit ima-
tinib binding [13]. However, mutation or amplification is
not observed in 50% or more of IM-resistant CML
patients [14–16] and the molecular basis of such BCR-
ABL-independent imatinib resistance is poorly
understood.
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Autophagy (self [auto]-eating [phagy]) is a lysosomal recy-
cling mechanism that leads to sequestration of intracellular
components into autophagosomes and lysosomal degradation
by autophagosome-lysosome fusion [17]. Autophagy initia-
tion starts with the activation of ULK1 and AMBRA1 com-
plexes following AMPK activation and MTOR inhibition
[18,19]. Interestingly, autophagy induction leads to depho-
sphorylation of AMBRA1 and interaction with the E3-ligase
TRAF6 to support Lys63-linked ubiquitination of ULK1, and
its subsequent activation [19]. Notably, the inhibition of BCR-
ABL by TKIs induces autophagy [20] that is a cell-survival
response in CML stem cells [21]. Several recent studies have
shown that the combination of TKIs and autophagy inhibitors
represent an effective treatment for CML [22–25]. However,
the molecular bridge linking autophagy with imatinib resis-
tance remains in vague.
GCA (grancalcin) is a cytosolic protein that is translocated
to the granule membrane upon neutrophil activation [26,27].
It belongs to a group of EF-hand Ca2+ binding proteins
including CAPN (calpain), ALG2, and SRI (sorcin), which
show structural rather than functional similarity [28].
Although it has been reported that GCA modulates Toll-like
receptor 9 (TLR9)-mediated signaling via direct interaction
with TLR9 [29], a genetic knockout of GCA in mice failed to
show relevant phenotypes and the physiological role of GCA
remains to be elucidated [30].
In this report, we identified GCA as a potential novel
molecule driving imatinib resistance in CML-CP through
activating autophagy. Our study showed that GCA facilitates
K63-linked ubiquitination of ULK1 by activating TRAF6,
resulting in autophagy induction, which is critical for imatinib
resistance in CML patients. These findings open new perspec-
tives for the treatment of CML.
Results
GCA was highly expressed in imatinib-resistant CML-CP
patients
To identify candidate genes for imatinib resistance in CML-CP
patients, we performed microarray-based transcriptome profil-
ing of peripheral blood mononuclear cells (PBMCs) obtained
from two groups: imatinib-sensitive (achieving major molecular
response within 6 months of imatinib treatment, with no BCR-
ABL mutations detected; n = 5) and resistant (CP but, no
cytogenetic response within 6 months of imatinib treatment,
and BCR-ABL mutations were not detected; n = 6) patients
(Figure 1a). We also confirmed BCR-ABL mRNA expression in
the same samples indicating that imatinib treatment was effec-
tive in sensitive but not in the resistant group (Figure S1a). We
selected 970 candidate genes based on fold change greater than
1.5 and a p-value less than 0.01 (Supplementary Material 1) and
performed unsupervised clustering. Two major clusters
emerged: one group of 5 imatinib-sensitive patients clustered;
another group of 6 imatinib-resistant samples clustered, of
which most genes are upregulated while some portion of genes
are downregulated in imatinib-resistant CML-CP patients
(Figure S1b). Accordingly, principal component analysis
(PCA) showed successful transcriptomic reprogramming in
imatinib-resistant patient group away from imatinib sensitive
patient group (Figure S1c). For further analysis, microarray data
were submitted to Ingenuity Pathway Analysis (IPA). The dif-
ferentially expressed genes were categorized to specific diseases
and biological functions based on Ingenuity pathway knowledge
base (IPKB). The top 15 enriched categories of specific diseases
and biological functions are listed in Table S2 and GCA belongs
to 11th (Figure S1D).
Since imatinib treatment depleted BCR-ABL-positive CML
cells in sensitive patients, the CML patient array data set com-
pared normal PBMC with CML cells rather sensitive cells with
resistant CML cells. To identify the genes involved in imatinib
resistance, we used previous transcriptome analysis of imatinib-
resistant K562 (K562IMres) and parental K562 cells (Figure 1a).
We previously reported 69 genes specifically induced in
K562IMres cells [31]. Interestingly, cross-analysis of two tran-
scriptomes revealed that mRNA of 6 genes are overlapped.
ADM (adrenomedullin), GCA (grancalcin), TAP1 (transporter
1, ATP binding cassette subfamily B member), LRMP (lymphoid
restricted membrane protein), PTPRC (protein tyrosine phos-
phatase, receptor type C) and SYK (spleen associated tyrosine
kinase) were significantly upregulated both in K562IMres cells
and imatinib-resistant CML patient group (Figure 1b and
Supplementary Material 2). In reviewing previous literature,
ADM, TAP1, SYK, and PTPRC were reported as induced genes
after imatinib treatment. ADM highly expressed in mouse heart
tissue after imatinib treatment [32]. TAP1 is upregulated by
imatinib treatment in dermatofibrosarcoma protuberans
patients carrying fibrosarcomatous transformation [33].
Imatinib binds an unphosphorylated kinase domain of SYK to
inhibit its kinase activity [34]. PTPRC is highly expressed in
primary CML cells and negatively modulates imatinib and nilo-
tinib response [35]. Among those genes, GCA and LRMP have
not been explored in the aspect of imatinib resistance. Next, we
tested whether reduced expression of 6 genes with siRNAs could
increase cellular sensitivity to imatinib in K562 cells. We found
that knockdown of 4 genes, including GCA, ADM, LRMP, or
PTPRC, significantly increased cellular sensitivity to imatinib
while knockdown of SYK and TAP1 did not significantly
improve the response to imatinib (Figure 1c and S2a-b). Of
note, the effect of GCA knockdown on imatinib treatment was
most pronounced compared to other genes and further con-
firmed with 3 independent siRNA of GCA (Fig. S2C-D). Taken
together, we focus on the function of GCA on imatinib resis-
tance in CML.
To emphasize the clinical significance, we evaluated the
GCA mRNA level in 9 paired clinical samples from 4
imatinib-sensitive patients and 5 imatinib-resistant patients
at diagnosis (Dx) and after imatinib treatment using qRT-
PCR assay. As shown in Figure 1d, imatinib treatment
strongly induced GCA mRNAs only in patients with pri-
mary resistance but not in imatinib-sensitive patients.
Imatinib treatment greatly reduced major BCR-ABL1:ABL1
mRNA ratio (IS) in sensitive patients with low level of GCA
expression, but not in resistant patients with high level of
GCA expression (Figure S3a and S3b-c). Importantly, the
protein levels of GCA from the imatinib-resistant patient
were gradually increased by following imatinib treatment
for 6 to 12 months (Figure 1e, right panel). In striking
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contrast, GCA protein levels were reduced by 6 months of
imatinib treatment in sensitive patients (Figure 1e, left
panel). The level of GCA protein is positively correlated
with major BCR-ABL1:ABL1 mRNA ratio after imatinib
CML Patients















































































































































































































































Figure 1. GCA was induced in imatinib-resistant CML patient-derived primary leukemia cells. (a) The workflow for the screening of genes is related to imatinib
resistance. (b) Venn diagram showing the overlap between K562IMresist cells and imatinib resistant CML patient group (top panel). The differential gene expression for
the overlapped 6 genes with a change in their expression between good response (GS) patients and primary resistant (PR) patients plus hierarchical clustering on
entities using euclidean distance with averaged linkage analysis (bottom panel). (c) The knockdown effect of 6 overlapped genes on imatinib resistance. K562 cells
were transfected with indicated siRNAs, treated with imatinib (0 or 250 nM) for 48 h and stained with ANXA5 for FACS analysis. The ratio (%) of the apoptotic cell was
graphed with S.D. as an error bar; Student’s t-test, **p < 0.01, ***p < 0.001, ns = non-significant. (d) The mRNA levels of GCA were analyzed by qRT-PCR in CML
patient-derived PBMCs; Dx (after diagnosis), MMR (major molecular response), Resist (resistance). (e) The protein levels of GCA were analyzed by immunoblotting
with the samples from two imatinib-sensitive patients after diagnosis (Dx) and 6 months imatinib treatment with MMR (left panel) and a imatinib-resistant patient
after diagnosis, 6 and 12 months imatinib treatment with Resist (right panel). (f) GCA and phosphorylated CrkL (p-CrkL) were analyzed by flow cytometry using PBMC
from CML-CP patients (#1420) at diagnosis and after 12 months of IM (imatinib) treatment.
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treatment (Figure S3b-c), indicating that GCA played
a critical role in primary imatinib resistance of CML-CP
patients.
To address whether GCA is induced in Ph+ CML cells
after imatinib treatment, we performed the co-
immunostaining for p-CrkL and GCA of the imatinib-
restitant patient sample (#1420) followed by FACS analysis.
As shown in Figure 1f, the portion of p-CrkLhighGCAhigh cells
was 28.5% at diagnosis and greatly increased to 66.1% after
12 months of imatinib treatment in a resistant patient
(#1420). Interestingly, the portion of p-CrkLlow GCAhigh
cells was not significantly reduced. Taken together, GCA
was mainly induced in the p-CRkL positive CML cells to get
imatinib resistance.
GCA inhibited imatinib-induced apoptotic cell death in
K562 and primary CML cells
To investigate the role of GCA in imatinib resistance, we used
imatinib-resistant (K562IMres) and GCA overexpressed K562
(K562GCA) cells for the viability test after imatinib treatment
(250–1000nM). Of note, K562IMres cells expressed higher levels
of GCA protein than parental K562 cells (Figure S4a). We
observed a significant resistance to imatinib in K562GCA similar
to K562IMres (Figure S4b). We further showed that imatinib-
induced apoptosis was significantly increased byGCA knockdown
in K562IMres cells (Figure 2a and S5a-b). Conversely, GCA over-
expression reduced imatinib-induced apoptosis (Figure 2b and
S5c) indicatingGCAprotein level is crucial for imatinib resistance.
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Figure 2. GCA inhibited imatinib-induced apoptosis through its LNT region. (a) K562IMres cells were transfected with control and GCA siRNA and treated with imatinib
(0.25, 0.8, 1.0 and 1.5 µM) for 48 h. Cells were stained with ANXA5 and analyzed by FACS. (b) K562 cells were transfected with MYC-tagged GCA (MYC-GCA) expression
plasmid and treated with imatinib (0, 100, 250 and 500 nM) for 48 h. ANXA5 positive apoptotic cells were analyzed by FACS. (c) Diagram of wild-type and siRNA
resistant mutants of GCA (Top panel). K562 cells were transfected with indicated combination and subject to western blot for GCA and ACTB. (d) K562 cells were
cotransfected with indicated combination of GCA siRNA and siRNA-resistant GCA expression plasmid (MYC-GCA Resist). The cells were treated with imatinib (0 or
250 nM) and subjected to the FACS analysis to analyze apoptotic cells. (e) Diagram of wild-type and five deletion mutants of GCA. (f) K562 cells were transfected with
wild-type and deletion mutants of GCA plasmid and treated with imatinib (0 or 250 nM) and subjected to the FACS analysis for apoptotic cells. (a, b, d, f) All graphs
illustrated the ratio (%) of ANXA5-positive apoptotic cells. The graphs show the average of three independent experiments. The error bars indicate the S.D. Student’s
t-test, **p < 0.01.
4 S. H. HAN ET AL.
resistance to imatinib-induced apoptosis (Figure 2c-d and S5d).
We also found that the LNT (lipophilic N-terminal extension)
region of GCA was mainly responsible for imatinib resistance
(Figure 2e-f and S5e).
To further investigate the clinical significance of GCA, we
evaluated the loss- and gain-of-function of GCA in PBMCs from
CML-CP patients. Using PBMCs from 5 independent CML-CP
patients, we demonstrated that GCA knockdown significantly
increased imatinib-induced apoptosis (Figure 3a and S6a).
Conversely, GCA overexpression significantly reduced imatinib-
induced apoptosis in PBMCs from 5 independent CML-CP
patients (Figure 3b and S6b). Together, our data strongly suggested
that GCA induces imatinib resistance in primary CML cells.
GCA induced autophagy related to imatinib resistance
It has been reported that imatinib treatment induces
autophagy in various mammalian cells [20]. More impor-
tantly, autophagy promotes imatinib resistance in CML
[24] and autophagy inhibitor was clinically tested in com-
bination with imatinib (ClinicalTrials.gov Identifier:
NCT01227135) [36]. Consistent with previous reports,
K562 cells showed a higher sensitivity to imatinib when
autophagy was inhibited by ATG5 siRNA (Figure S7). To
investigate the role of GCA in autophagy, we assessed
autophagy activation by monitoring autophagosome-
associated LC3-II using western blot and immunofluores-
cence staining of LC3. K562GCA cells showed more autop-
hagosome-associated LC3-II than K562puro cells (Figure
S8a), which was reversed by GCA knockdown (Figure
4a-b). Consistently, K562IMres cells showed greater levels
of autophagosome-associated LC3-II than K562 cells
(Figure S8b), which were reversed by GCA knockdown
(Figure 4c-d). We also showed that SQSTM1/p62, the
autophagy marker, was decreased in K562GCA and
K562IMres cells, indicating autophagy activation (Figure
S8a-b, left panel). To further demonstrate autophagy acti-
vation by GCA, we performed autophagy flux analysis in
which the clearance of autophagosomes by lysosomes was
determined by the rate of LC3-II degradation [37]. As
shown in Figure 4e-f, autophagic flux of K562GCA and
K562IMres cells was higher than their control in basal
state. After imatinib treatment, autophagic flux was
increased in K562GCA and K562IMres cells. Together, our
data indicate that GCA is a novel positive regulator of
autophagy.
GCA inhibited proteasomal degradation of ULK1
The regulation of ULK1 is a key mechanism underlying
autophagy activation [19]. Interestingly, K562IMres cells
showed high-level expression of ULK1 (Figure 5a),
which was reduced by GCA knockdown (Figure 5b).
Consistently, K562GCA showed higher levels of ULK1
protein (Figure 5c), suggesting that GCA expression is
positively correlated with ULK1 expression. The protein
stability assay of ULK1 using cyclohexamide revealed that
ULK1 was more stable when GCA was highly expressed
and vice versa (Figure 5d and S9a). As shown in Figure
5e, ULK1 was greatly increased within the imatinib treat-
ment period in K562GCA cells compared with K562puro
cells. In striking contrast, ULK1 was almost unchanged
during imatinib treatment when GCA was knocked down
(Figure S9b). These results suggested that GCA stabilized
ULK1 under imatinib treatment.
ULK1 protein level is controlled by proteasomal degra-
dation [38]. As shown in Figure 5f, the protein level of
ULK1 was increased in K562GCA cells (lane 5) and suc-






























































































































































































Figure 3. GCA regulated imatinib resistance in CML patient-derived primary leukemia cells. (a) PBMCs derived from 5 independent CML-CP patients were transfected
with control and GCA siRNAs and (b) PBMCs from 5 independent CML-CP patients were transfected with MYC-tagged GCA (MYC-GCA) expression plasmid. The cells
were treated with imatinib (0, 250 nM) for 48 h and stained with ANXA5 for FACS analysis. All graphs illustrated the ratio (%) of ANXA5-positive apoptotic cells. The
graphs show the average of three independent experiments. The error bars indicate the S.D. Student’s t-test, **p < 0.01.
AUTOPHAGY 5
Interestingly, treatment with proteasomal inhibitor
(MG132) restored ULK1 protein level in GCA knocked
down cells (lane 8) suggesting that GCA stabilized ULK1
by inhibiting its proteasomal degradation. K48-linked and
K63-linked polyubiquitination of ULK1 mediates protea-
somal degradation [39] and self-association respectively
[19,40]. To determine the polyubiquitination chain type
of ULK1 induced by GCA, HA-tagged K48 only or K63
only ubiquitin was expressed with ULK1 and GCA
(Figure 5g). Overexpressed GCA inhibited K48-linked
polyubiquitination of ULK1 (lane 3), which is extensively
linked to proteasomal degradation [39]. In contrast, GCA
overexpression induced K63-linked polyubiquitination of
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Figure 4. GCA activated autophagy to induce imatinib resistance. (a) K562GCA cells were transfected with control and GCA siRNAs and subjected to immunoblotting
for LC3-I, LC3-II, MYC-tag and ACTB along with K562puro. (b) The same cells were immunostained for LC3 to visualize autophagosomes (green) and stained with DAPI
for nuclei (blue). Scale bar, 10 μm. The area of LC3 is quantified by ImageJ software. The graph showed the average of three independent experiments with error bar
(S.D.). Student’s t-test, *p < 0.05, ***p < 0.001 (c-d) K562 and K562IMres cells were subjected to the same experiment in Figure 4a–b. (e) The autophagic flux
quantification of K562puro and K562GCA cells. The cells were treated with imatinib (0.5 µM) for 3 h with/without lysosomal inhibitors (NH4Cl & E-64-d). Representative
western blots (left panel) and the graph show the average of three independent experiments (right panel). The error bars indicate the S.D. Student’s t-test, *p < 0.05,
**p < 0.01. (f) K562 and K562IMres cells were subjected to the same experiment for the autophagy flux quantification in Figure 4e.
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GCA induced k63-linked polyubiquitination of TRAF6
resulting in its dimerization and activation to
ubiquitinate ULK1
TRAF6 is an ubiquitin ligase mediating K63-linked polyubi-
quitination for itself and ULK1 resulting in their homodimer-
ization and autophagy activation [19]. We showed that self-
ubiquitination of TRAF6 was increased by GCA overexpres-
sion (Figure 6a), which was inhibited by knockdown of endo-
genous GCA (Figure 6b) indicating the role of GCA in the
self-ubiquitination of TRAF6. To determine the chain type of
polyubiquitination by GCA, HA-tagged K48 only or K63 only
ubiquitin was expressed with TRAF6 and GCA (Figure 6c).
Importantly, overexpressed GCA induced K63-linked polyu-
biquitination (lane 5) but not K48-linked polyubiquitination
of TRAF6 (lane 3). It has been reported that K63-linked
polyubiquitination of TRAF6 induces its dimerization to acti-
vate downstream signaling [41]. To address the role of GCA
in TRAF6 dimerization, we transfected Flag-TRAF6, HA-
TRAF6 and GCA expression plasmids into K562 cells fol-
lowed by immunoprecipitation with anti-Flag antibody
(Figure 6d). HA-TRAF6 was co-immunoprecipitated with
Flag-TRAF6 (lane 1), which was induced by GCA expression
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Figure 5. GCA stabilized ULK1 by inhibiting its K48-linked ubiquitination. (a) K562 and K562IMres cells were subjected to immunoblotting for ULK1, GCA,
and ACTB. (b) K562IMres cells were transfected with control, GCA #1 and #2 siRNAs. Cell lysates were subjected to immunoblotting for ULK1, GCA and
ACTB. (c) K562puro and K562GCA cells were lysed and subjected to immunoblotting for ULK1, MYC-tag (GCA) and ACTB. (d) K562puro and K562GCA cells
were treated with cycloheximide (CHX) for the indicated times and subjected to immunoblotting for ULK1, MYC-tag (GCA) and ACTB (top panel). Relative
expression of ULK1 is graphed (bottom panel). (e) K562puro and K562GCA cells were treated with 250 nM imatinib for the indicated time. The cell lysates
were immunoblotted analysis of ULK1, MYC-tag (GCA) and ACTB (top panel). Relative expression of ULK1 from 3 independent experiments is plotted
(bottom panel). The error bars indicate the S.D. Student’s t-test, **p < 0.01. (f) K562puro and K562GCA cells were transfected with control (defined as ‘C’)
and GCA siRNA and treated with/without 20 μM MG132 for 6 h. Cells were lysed and subjected to immunoblotting for ULK1, MYC-tag (GCA) and ACTB. (g)
K562 cells were transfected with the indicated expression plasmids. Cell lysates were subjected to immunoprecipitation with anti-Flag antibody (for SFB-
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Figure 6. GCA activated TRAF6-dependent K63-linked ubiquitination of ULK1. (a) The effect of GCA expression in TRAF6 ubiquitination. Flag-TRAF6, MYC-tagged GCA
(MYC-GCA) and HA-Ubi expression plasmids were transfected into the K562 cell as an indicated combination. Cells were lysed and subjected to immunoprecipitation
using anti-Flag antibody. Cell lysates and immunoprecipitated samples were analyzed by immunoblotting using anti-Flag, HA and MYC antibodies. (b) Flag-TRAF6,
HA-Ubi were co-transfected into K562 cells with control and GCA specific siRNA as indicated combination and ‘C’ indicated a control siRNA. Cell lysates and
immunoprecipitated samples were subjected to immunoblotting using anti-Flag and -HA antibodies. (c) GCA activates TRAF6-dependent K63-linked ubiquitination.
K562 cells were transfected with the indicated expression plasmids and immunoprecipitated with anti-Flag antibody (TRAF6). Cell lysates and immunoprecipitated
samples were subjected to immunoblotting analysis of HA (ubiquitin), Flag (TRAF6) and MYC-tag (GCA). (d) The effect of GCA expression in TRAF6 dimerization. K562
cells were transfected with Flag-TRAF6, HA-TRAF6 and MYC-GCA as an indicated combination. Cell lysates were subjected to immunoprecipitation with anti-Flag
antibody. Cell lysates and immunoprecipitated samples were subjected to immunoblotting using anti-HA, Flag and MYC antibodies. (e) GCA induces TRAF6-
dependent ubiquitination of ULK1. K562 cells were transfected with the indicated expression plasmids and immunoprecipitated with anti-Flag antibody (ULK1). Cell
lysates and immunoprecipitated samples were subjected to immunoblotting analysis for MYC-tag (ubiquitin), Flag (ULK1) and HA (TRAF6). (f) K562 cells were
cotransfected with SFB-ULK1, MYC-Ubi and HA-TRAF6 expression plasmids in combination with control ‘C’ and GCA siRNA. Cell lysates and immunoprecipitated
samples were subjected to immunoblotting using anti-Flag, -MYC and -HA antibodies. (g) K562 cells were cotransfected with the indicated expression plasmids in
combination with control and TRAF6 siRNA. Cell lysates were immunoprecipitated with anti-Flag antibody (ULK1). Cell lysates and immunoprecipitated samples were
subjected to immunoblotting analysis of MYC-tag and Flag.
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(lane 3). Taken together, GCA activated self K63-linked poly-
ubiquitination of TRAF6 resulting in its homo-dimerization.
To investigate TRAF6 activation by GCA to ubiquiti-
nate ULK1, we tested whether GCA induces a TRAF6-
dependent ubiquitination of ULK1. As shown in Figure
6e, the overexpressed GCA induced ULK1 ubiquitination
by TRAF6 (lane 4). We also showed inhibition of TRAF6-
mediated ubiquitination of ULK1 by endogenous GCA
knockdown (Figure 6f). Importantly, GCA-induced ULK1
ubiquitination was inhibited by endogenous TRAF6
knockdown (Figure 6g, lane 4). Taken together, GCA
activates TRAF6 via K63-linked polyubiquitination to pro-
mote the K63-linked ubiquitination of ULK1.
GCA-TRAF6-ULK1 regulatory axis controlled imatinib
resistance through induction of autophagy
To address the role of the GCA-TRAF6-ULK1 regulatory axis in
autophagy, we investigated the role of endogenous TRAF6 or
ULK1 knockdown in the inhibition of autophagy of K562IMres
cells and K562GCA cells. As shown in Figure 7a-d, TRAF6 or
ULK1 knockdown inhibited LC3-II and autophagosome forma-
tion in both K562GCA and K562IMres, suggesting that the GCA-
TRAF6-ULK1 regulatory axis controls autophagy. Notably, the
ULK1 protein level was increased in K562IMres and K562GCA
cells, which was not reduced by TRAF6 knockdown indicating
that TRAF6 was not responsible for ULK1 stabilization in those
cells (Figures 7a and 7c, lane 4).
To determine if the GCA-TRAF6-ULK1 regulatory axis con-
trolled imatinib resistance, we showed that imatinib-induced
apoptosis was significantly increased in three independent
TRAF6 or ULK1 siRNA-transfected K562 cells (Figure 7e-f and
S10a-b). Importantly, we examined the hypothesis in primary
CML cells derived from CML-CP patients. Although the degree
of apoptosis varied among patient-derived primary CML cells,
a single knockdown of GCA, ULK1 or TRAF6 consistently
induced higher levels of apoptosis after imatinib treatment
(Figure 8a and S11a). In addition, a double-knockdown of
GCA & ULK1 or GCA & TRAF6 significantly increased apop-
totic cell death after imatinib treatment (Figure 8b-f and S11b-f)
indicating synergistic effect. These data indicated that GCAplays
a critical role in imatinib-induced apoptosis via TRAF6-ULK1
autophagy regulatory axis.
GCA controlled imatinib resistance without altering
tumor growth
To test if GCA expression enhanced imatinib resistance in vivo, we
used a mouse xenograft model. K562puro and K562GCA cells were
subcutaneously injected into mice. After 20 days of injection,
imatinib was orally administered for another 15 days and the
tumor size was monitored (Figure 9a). Before imatinib adminis-
tration, there was no significant difference in tumor volume
betweenmice injected with K562puro andK562GCA cells indicating
that GCA did not affect tumor growth (Figure S12a). We also
found that cell growth rates were not different between K562puro
and K562GCA cells (Figure S12b). During imatinib treatment for
another 15 days, imatinib successfully reduced tumor size in
K562puro-injected mice group (Figure 9b, red line). In contrast,
xenograft tumors produced by K562GCA cells did not show
a significant change in tumor size (Figure 9b, dark blue line).
After 35 days of injection, all mice were sacrificed, and tumors
were dissected for further analysis. As shown in Figure 9c, imatinib
treatment greatly reduced the tumor size in K562puro-injected
mice. However, the tumor size of K562GCA-injected mice was
not altered by imatinib treatment, suggesting that GCA regulated
imatinib resistance in vivo. Notably, the ULK1 protein level was
higher in K562GCA than in K562puro xenograft tumors with ima-
tinib administration, suggesting that GCA play a role in ULK1
protein stability (Figure 9d). Additionally, we demonstrated that
the phosphorylation of STAT5, a BCR-ABL substrate, was reduced
by imatinib treatment in both CML cells and CML cells-derived
tumors indicating the proper inhibitory effect of imatinib for BCR-
ABL kinase (Figure S13a-b).
In conclusion, we demonstrated that GCA was highly
expressed in both imatinib-resistant K562 cells and primary
patient cells, suggesting GCA was a potential genetic marker
for imatinib resistance. We also showed that GCA stabilized
ULK1 by inhibiting its proteasomal degradation and activated
autophagy by controlling TRAF6-dependent K63-linked ubi-
quitination of ULK1, which is a critical regulatory axis in
imatinib resistance (Figure 9e).
Discussion
For more than a decade, imatinib methylate was considered as
the first ‘targeted’ anticancer drug with clinical success [9,42].
Despite these impressive results, a minority of CML patients
in chronic phase (CML-CP) and a significant proportion of
CML patients in advanced phase are either initially resistant
to imatinib treatment or acquire imatinib insensitivity over
time [13,43]. The contribution to such secondary resistance by
mutations in the BCR-ABL kinase domain was much lower in
patients with CP than in advanced phase [44,45], underscor-
ing the significance of BCR-ABL-independent mechanism for
imatinib resistance.
In microarray screening of imatinib-resistant patient sam-
ples without BCR-ABL mutations and imatinib resistant K562
cells (K562IMres), we found that GCA, ADM, LRMP, PTPRC,
SYK and TAP1 are highly expressed. Among them, GCA was
identified as a potential novel regulator of imatinib-resistance
and GCA knockdowned CML cells was most sensitive to
imatinib-induced apoptosis. This conclusion was further con-
firmed by a murine xenograft experiment demonstrating that
GCA expression enhanced imatinib resistance. These results
indicate that GCA is a critical regulator as well as a genetic
marker for imatinib resistance. Interestingly, GCA overex-
pression failed to induce in vitro cell growth as well as
in vivo tumor growth (Figure S12), rather it regulates imatinib
resistance. Notably, GCA expression was greatly increased by
imatinib treatment of CML-CP patients (Figure 1d). In con-
trast, GCA expression was reduced in imatinib sensitive CML
patients suggesting that GCA is a key regulator underlying
imatinib resistance in CML.
GCA is specifically expressed in cells of myeloid lineage,
such as neutrophils and monocytes/macrophages, and is
known as a cytosolic protein that is translocated to granules
and plasma membrane upon neutrophil activation [26,46].
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Based on available evidences supporting the role of GCA in
cytoplasmic localization, myeloid lineage-specific expression
and imatinib resistance in CML, it is plausible that GCA plays
a critical role in cytoplasmic mechanisms that regulate
imatinib resistance, possibly via autophagy. Autophagy is
considered key to understanding BCR-ABL1-independent
imatinib resistance, although the mechanism has yet to be






























































































































































Figure 7. GCA induced autophagy through ULK1-TRAF6 regulatory axis to control imatinib resistance. (a) K562 and K562IMres cells were transfected with control, ULK1
or TRAF6 siRNAs. Cell lysates were subjected to immunoblotting analysis of LC3-I, LC3-II, ULK1, TRAF6, GCA and ACTB. (b) The same samples were immunostained
with LC3 to visualize autophagosomes (green) and DAPI for nuclei (blue). Scale bar: 10 μm. (c) K562puro and K562GCA cells were transfected with control, ULK1 or
TRAF6 siRNAs. Cell lysates were subjected to immunoblotting for LC3-I, LC3-II, ULK1, TRAF6, MYC-tag GCA and ACTB. (d) The same samples were immunostained with
LC3 to visualize autophagosomes (green) and DAPI for nuclei (blue). Scale bar: 10 μm. (e-f) K562 cells were transfected with control and 3 independent ULK1 siRNAs
(e) or 3 independent TRAF6 siRNAs (f) and subjected to apoptosis analysis by FACS. The ratio (%) of the apoptotic cell was graphed with S.D. as error bar (top panel)
and knockdown efficiency checked using western blot indicated antibodies (bottom panel). Student’s t-test, **p < 0.01.
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overexpression itself activates autophagy, resulting in imatinib
resistance in leukemia cells and vice versa (Figure 4). These
results point to GCA as a novel regulator of autophagy,
related to imatinib resistance in CML-CP.
GCA interacts with TLR9 activating TRAF6-mediated proin-
flammatory cytokine/chemokine production [29]. TRAF6,
a specific RING finger E3 ubiquitin ligase, has been proposed
to mediate the Lys63 ubiquitination of ULK1 contributing to
ULK1 activation, which induces autophagy [19]. Based on the
foregoing studies, we demonstrated that GCA activates TRAF6-
dependent K63-linked ubiquitination of TRAF6 and ULK1
(Figure 6) and also inhibits TRAF6-independent K48 ubiquiti-
nation of ULK1 (Figure 5) to induce autophagy resulting in
imatinib resistance in CML (Figure 7). We further showed that
imatinib resistance was abolished by the inhibition of GCA,
TRAF6 or ULK1 in the cells of CML patients (Figure 8), indicat-
ing that GCA controls imatinib resistance in CML via TRAF6-
ULK1 autophagy regulatory axis.
GCA regulates protein stability of ULK1 by inhibiting K48-
linked polyubiquitination (Figure 5). However, TRAF6 does
not mediate GCA-induced ULK1 stabilization (Figures 7a and
7c) or K48-linked ubiquitination of ULK1 (Figure 6c) suggest-
ing the role of another ubiquitin ligase. It was reported that
ULK1 undergoes K48-linked polyubiquitination mediated by
another ubiquitin ligase, CUL3-KLHL20, for degradation dur-
ing prolonged autophagy [48]. Thus, it is plausible that GCA
inhibits CUL3-KLHL20 or another K48-linked ubiquitin
ligase to stabilize ULK1. These phenomena explain the syner-
gistic effect of GCA with ULK1 or TRAF6 dual knockdown
on imatinib-induced apoptosis.
In this paper, we do not have a chance to address how
imatinib induces GCA expression. Interestingly, it has been
reported that imatinib treatment induces the expression of
MIR146A in CML patients [49,50]. Notably, MIR146A
induces GCA expression in hepatic stellate cells [51]. Taken
together, it is plausible that MIR146A also induces GCA
expression in CML patients after imatinib treatment. In addi-
tion, we could not exclude the possibility that BCR-ABL
regulates GCA expression. Therefore, it would be a valuable
future study to address the role of MIR146A or BCR-ABL on
GCA induction in response to imatinib.
In summary, we identified GCA as a novel regulator of
imatinib resistance in CML. GCA stabilized and activated
ULK1 to induce autophagy. We also highlighted the novel
role of GCA in K63-linked ubiquitination of ULK1 by TRAF6
to activate autophagy resulting in imatinib resistance in CML.
Notably, GCA regulated autophagy suggesting a novel ther-
apeutic strategy in TKI-resistant CML patients.
Materials and methods
Patient samples and cell lines
Peripheral blood mononuclear cells (PBMCs) were obtained
from 32 CML-CP patients after diagnosis (Dx), imatinib
treatment for 6 months with major molecular response
(MMR) or resistance (Resist). All patient characteristics/
demographics were listed in Table S1. PBMCs were isolated
by Ficoll-Paque (GE Healthcare, 17,144,003) density-gradient
centrifugation. The 11 CML-CP patients (GS: good response
and PR: primary resistance) provided PBMCs after 6 months
of imatinib treatment for microarray analysis. Parental K562,
imatinib-resistant K562 (K562IMres), MYC-GCA stably
expressing K562 (K562GCA) and its control (K562puro) cell
lines were used for experiments. All patient samples were



































































































































Figure 8. GCA-TRAF6-ULK1 regulatory axis controlled imatinib resistance in CML-CP patient-derived primary CML cells. PBMCs from 6 independent CML-CP patients
(a) #2038, (b) #2115, (c) #2128, (d) #2041, (e) #2042 and (f) #2055 were transfected with indicated siRNAs and treated with/without 250 nM imatinib for 48 h followed
by FACS analysis for apoptotic cells. The graph shows the average of three independent experiments. The error bars indicate the S.D. Student’s t-test, **p < 0.01.
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Institutional Review Board (KC14SEME0280). Patient consent
was obtained in accordance with the Declaration of Helsinki.
Cell culture
K562, K562IMres, K562puro and K562GCA cell line were main-
tained in RPMI medium (GIBCO, 11,875–093) supplemented
with 10% fetal bovine serum (GIBCO, 12,483–020) at 37°C in
5% CO2 (v/v). To establish GCA stable cell lines, K562 cells
were transfected with MYC-GCA expression plasmid or
empty vector as a control, using microporation according to
the manufacturer protocol (Neon system, Invitrogen). MYC-
GCA stably expressed (K562GCA) and control K562 cells
(K562puro) were selected with puromycin (2 µg/ml, GIBCO,
A1113802) for 14 days.
Transfection
Transient transfection was performed using the Neon
Transfection System (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s protocol. Briefly, K562 cells or
PBMCs (2x106 ~ 1x107cells) were transfected with total
20 µg of plasmid or 200 nM siRNAs using microporator
(1450 V for 15 ms in 2 pulses for K562 cells; 1,750 V for
20 ms in 1 pulse for PBMCs) and incubated in pre-warmed
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Figure 9. GCA controlled the imatinib resistance without an influence on tumor growth. (a) Experimental design for the analysis of imatinib resistance using
Xenograft. K562puro and K562GCA cells were subcutaneously injected. After 20 days of tumor cell injection, imatinib was administered for another 15 days. (b) Tumor
growth of K562puro and K562GCA cells after imatinib treatment. After 20 days of tumor injection, K562puro and K562GCA cells were divided into control and imatinib
treatment group (oral). Tumor size was measured at 0, 3, 7, 10, 14 days of imatinib administration. Tumor volume was plotted with S.E. as error bar (ns: no significant,
*: p < 0.05 **: p < 0.01, ***: p < 0.001) (right panel). (c) Xenograft tumor was dissected at 35 days after injection and imaged with scale (left panel). Tumor volume
was measured and plotted with S.E. as error bar (***: p < 0.001) (right panel). (d) Dissected tumors were lysed and subjected to immunoblotting for ULK1, MYC-tag
(GCA) and ACTB (top panel). The relative intensity of ULK1 (ULK1:ACTB) was graphed with S.D. as error bar (*: p < 0.05) (bottom panel). (e) The proposed model of
GCA-TRAF6-ULK1 regulatory axis to induce autophagy resulting in imatinib resistance.
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FBS (GIBCO, 12,483–020) for 24 h or 48 h. siRNA sequences
are provided in supplementary information.
Chemicals
Imatinib mesylate (Selleckchem, S1026) was dissolved in
DMSO at a stock concentration of 10 mM stock and stored
at −20°C. Puromycin was purchased from Invivogen
(Invivogen, ant-pr-1). MG132 (AG scientific, M-1157) was
dissolved in DMSO and stored at −20°C, and lysosome inhi-
bition was achieved using 20 mM NH4Cl (Sigma-Aldrich,
A9434) and 10 µg/ml E-64-d (Santa Cruz Biotechnology, sc-
201280A).
Plasmids
The GCA (hMU009399) clone was obtained from the Korea
Human Gene Bank, Medical Genomics Research center, KRIBB,
Korea. The MYC-GCA expression vector, MYC-GCA internal
deletion mutants or GCA siRNA resistance plasmid were gen-
erated by PCR. The Flag-TRAF6, ULK1 expression plasmid was
kindly provided by Dr. Seok Hee Park (Sungkyunkwan
University, Korea). SFB-ULK1 was cloned into a Gateway-
compatible destination vector harboring an N-terminal SFB
tag (S-protein, a FLAG epitope, and a streptavidin-binding
peptide). The HA-TRAF6 expression plasmid was kindly pro-
vided by Dr. Sungkyu Park (GIST, Korea).
Antibodies
The rabbit anti-GCA antibody was produced by immunizing
rabbits with the full sequence of the GCA protein expressed in
a GST-vector. The rabbit polyclonal anti-GCA antibodies
were affinity-purified using the Aminolink Coupling Gel
Column Kit (ThermoFisher Scientific, 20,501). Human anti-
ULK1 (Cell Signaling Technology, 8054), and anti-LC3A/B
(Cell Signaling Technology, 12,741), anti-MYC (Roche,
11,814,150,001), anti-TRAF6 (Santa Cruz Biotechnology, sc-
8409), anti-HA (Roche, 12,013,819,001), anti-Flag (Sigma-
Aldrich, F3165), and anti-ACTB (Sigma-Aldrich, A5316) anti-
bodies were purchased.
Apoptosis assay
Apoptosis assay was performed using the FITC ANXA5
(annexin A5) Apoptosis Detection Kit I (BD bioscience,
556,547) according to the manufacturer’s protocol. Briefly,
K562 cells or PBMCs were transfected with the indicated
plasmids or siRNA in the figure legend. After 48 h, the
transfected K562 cells were plated in the flask or culture
dish and treated with the indicated concentration of imatinib
for 48 h. These cells were analyzed by fluorescence-activated
cell sorting, FACS (BD Bioscience, San Jose, CA, USA).
Flow cytometry for GCA and p-CrkL expression
PBMC from imatinib resistant CML patient (#1420) were
fixed with 1% PFA for 15 min. The cells were permeabilized
with PBT (0.2% Tween, 2% FBS (GIBCO, 12,483–020) in PBS
(GIBCO, 10,010,023)), for 15 min. The cells were stained with
anti-GCA (1:50) for 1 h on ice. The cells were washed twice
and co-stained with PE-conjugated-anti-p-CrkL (BD
Bioscience, 560,788) and FITC-conjugated anti-rabbit anti-
body (Jackson ImmunoResearch, 111–095-144) for 30 min.
The cells were washed twice with PBS and subjected to FACS
analysis (BD Bioscience, San Jose, CA, USA).
Autophagic flux assay
Autophagic flux assay was analyzed essentially as previously
described [52–54]. Briefly, K562 cells were treated with ima-
tinib (0.5 µM) for 3 h with/without a combination of E-64d
(10 µg/ml) plus NH4Cl (20 mM) to inhibit lysosomal pro-
teases and neutralize lysosomal pH, respectively. The treated
cells were subjected to western blot analysis using LC3 and
ACTB antibodies. The LC3-II bands were quantified using
Fusion Solo ChemiDoc system (Vilber, Collégien, France) and
normalized to ACTB bands. Autophagy flux is calculated by
subsidizing the lysosomal inhibitor-treated cells to non-
treatment cells in both basal and imatinib-treated condition.
Immunoprecipitation and western blot
K562 cells were transfected with indicated expression plas-
mids in each figure legend. After 48 h, the cells were lysed
in NETN buffer for 30 min on ice. Crude lysates were
cleared by centrifugation at 11,400 x g at 4°C for 15 min
and supernatants were incubated with protein A- or
G-agarose-conjugated primary antibodies. The immuno-
complexes were washed three times with NETN buffer and
subjected to sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE). Western blotting was performed
using the antibodies indicated in the figure legends. The
antibody dilutions for western blot were 1:1000 in 1% or 5%
skim milk or 4% BSA. HRP-conjugated anti-rabbit IgG
(Sigma-Aldrich, A0545) or anti-mouse IgG (Sigma-Aldrich,
A9917) IgG were used for detection. The immunoreactive
protein signals were identified using home-made electroche-
miluminescence (ECL) detection reagents. The signal inten-
sity of detected protein was normalized to that of ACTB
(Sigma-Aldrich, A5441) and analyzed using Fusion Solo
ChemiDoc system (Vilber, Collégien, France) and Bio1D
software (Fisher biotech, Australia). All targeted proteins
and internal loading controls were detected and verified
within the same linear range.
Cell viability assay
Cell proliferation was determined by the 3-[4,5-dimethylthia-
zol-2-yl]-2,5 diphenytetrazolium bromide (MTT; Sigma,
M5655). 2 × 104 cells/100 µL were seeded in a 96-well, flat-
bottom plate and treated with different concentrations of
imatinib for 48 h. 10 µL/well MTT (5 mg/mL) were added
and the plate was incubated for 2–4 h. The plate was centri-
fuged at 125 x g for 10 min and the supernatant were
removed. 100 µL of dimethyl sulfoxide (DMSO) were added
to each well to solubilize the formazan crystals. Absorbance
AUTOPHAGY 13
was measured at 570 nm using a microplate reader
(VersaMax, Molecular Devices, San Jose, CA, USA).
qRT-PCR
Total RNA was extracted with 1 ml of TRI reagent (Molecular
Research Center, TR 118) as the manufacture’s protocol. 1 ug
of total RNA was reverse transcribed using ReverTra Ace®
qPCR RT Master Mix with gDNA Remover (Toyobo, FSQ-
301). A quantitative real-time PCR (qRT-PCR) was performed
using a SYBR ® Green Realtime PCR Master Mix (Toyobo,
QPK-201). The temperature profile for the reaction was as
follows: 95°C for 30 s; 95°C for 5 s; 55°C for 10 s; 72°C for 15 s
for 40 cycles and melting curve were analyzed with a ramp
speed of 0.2°C increment between 95°C and 65°C. The relative
quantity was determined by the comparative threshold cycle
(Ct) method, and the results were normalized by GAPDH.
Primers are listed in supplementary information.
Immunofluorescence staining
K562 cells were seeded on lysine-coated slides by cytocentri-
fuge, then fixed with 4% paraformaldehyde at room tempera-
ture for 10 min. The fixed cells were permeabilized with 0.2%
Triton X-100 (Sigma-Aldrich, T8787) in PBS at room tem-
perature for 5 min and blocked with 5% goat serum
(Invitrogen, 10000C) in PBS (GIBCO, 10,010,023) at room
temperature for 1 h. The cells were incubated overnight with
primary antibody at 4°C and then incubated with the second-
ary antibodies after washing with 0.1% Triton X-100 in PBS.
The cells were finally mounted using DAPI Fluoromount-G
(Invitrogen, 00–4958-02) and covered by coverslips.
Fluorescent images were captured by Olympus microscope
BX53 using MetaVue software under the same conditions.
Murine xenograft experiment
Animals were purchased from Nara Biotech in Korea and
housed in the pathogen-free mouse facility of Chungnam
National University. All procedures for animal experiments
were approved by the Institutional Animal Care and Use
Committee (CNU-00772). Five-week-old female BALB/c
nu/nu mice were subcutaneously injected with 1 × 107
cells/100 μl of either K562puro or K562GCA CML cells in
1X PBS mixed with matrigel® Matrix (Corning, 356,237) per
mouse. Twenty days after injection, mice were randomly
divided into 4 groups (n = 6 or 7) according to tumor
volume of approximately 200 mm3. We excluded mice with
tumors less than 200 mm3. We administered either imatinib
(100 mg/kg/day) or vehicle (0.5% methylcellulose) daily.
Tumor volumes were measured every 3 or 4 days interval
for 15 days. Tumor volumes were calculated using the
formula (L× W2/2), where L denotes the largest tumor
diameter and W represents the smallest tumor diameter.
After 15 days of treatment, mice were sacrificed, and
tumors were harvested and subjected to western blot.
Statistics
Statistical analysis was performed using the student’s t-test.
All experiments were performed at least three times and
graphs represent the average of three independent experi-
ments. The error bars indicate the SEM or S.D. P < 0.05 was
considered statistically significant.
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